Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline in the Class Action Lawsuit against Accretive Health, Inc.

Wed Jul 3, 2013 11:32pm EDT

* Reuters is not responsible for the content in this press release.

Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline in the Class Action Lawsuit against Accretive Health, Inc.

Glancy Binkow & Goldberg LLP announces that all purchasers of the securities of Accretive Health, Inc. (“Accretive” or the “Company”) (NYSE:AH) between May 20, 2010 and February 26, 2013 (the “Class Period’) have until July 19, 2013 to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Northern District of Illinois.

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER OR IF YOU PURCHASED ACCRETIVE STOCK PRIOR TO THE CLASS PERIOD. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

The Complaint alleges that during the Class Period defendants knew but misrepresented or failed to disclose to the investing public that: (1) the Company had improperly recognized revenue under certain managed service contracts; (2) the Company’s financial statements were not prepared in accordance with Generally Accepted Accounting Principles; (3) the Company lacked adequate internal and financial controls; and (4) as a result of the foregoing, the Company’s financial statements were materially false and misleading at all relevant times.

On February 26, 2013 Accretive announced that it will postpone the release of the Company’s financial results for the fourth quarter and full year 2012 because it is evaluating the timing of revenue recognition for its revenue cycle management agreements. In addition, Accretive withdrew its financial guidance previously provided on November 7, 2012. On this news, shares of Accretive declined almost 20%.

To learn more about this action or if you purchased Accretive stock prior to the Class Period and have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, (888) 773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh, (212) 682-5340
shareholders@glancylaw.com
www.glancylaw.com